Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages S46-S66

  Easterbrook, Philippa J ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Birth cohort; Dried blood spots (DBS); Focused testing; General population testing; Hepatitis C; Rapid diagnostic tests (RDTs); Testing

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIGEN; VIRUS RNA;

ANTIVIRAL THERAPY; BLOOD SAMPLING; CHRONIC HEPATITIS C; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRIED BLOOD SPOT TESTING; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH EQUITY; HEPATITIS B; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN RIGHTS; IMMUNOASSAY; LABORATORY TEST; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; NONHUMAN; NUCLEIC ACID ANALYSIS; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SELF CONCEPT; SEROLOGY; STAFF TRAINING; TREATMENT RESPONSE; VALIDATION PROCESS; VIREMIA; WORLD HEALTH ORGANIZATION; CHRONIC HEPATITIS B; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; GLOBAL HEALTH; MALE; PROCEDURES; RISK FACTOR; VIROLOGY;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; GLOBAL HEALTH; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; RISK FACTORS; VIROLOGY; WORLD HEALTH ORGANIZATION;

EID: 85013455987     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.002     Document Type: Review

References (207)

1. [1] Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
2. [2] Mortality, G.B.D., Collaborators CoD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
3. [3] Mathurin, P., HCV burden in Europe and the possible impact of current treatment. Dig Liver Dis 45 (2013), S314–S317.
4. [4] Mitchell, A.E., Colvin, H.M., Palmer, Beasley R., Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 51 (2010), 729–733.
5. [5] Papatheodoridis, G., Thomas, H.C., Golna, C., Bernardi, M., Carballo, M., Cornberg, M., et al. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat 23 (2016), 1–12.
6. [6] Yehia, B.R., Schranz, A.J., Umscheid, C.A., Lo, Re V., The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One, 9, 2014, e101554.
7. [7] Screening donated blood for transfusion transmissible infections. 2010, World Health Organization, Geneva http://www.who.int/bloodsafety/ScreeningDonatedBloodforTransfusion.pdf.
8. [8] Technical considerations and case definitions to improve surveillance for viral hepatitis. 2016, World Health Organization, Geneva http://www.who.int/hepatitis/publications/hep-surveillance-guide-pub/en/.
9. [9] Sixty-third World Health Assembly. Resolution WHA63.18 on viral hepatitis. 2010, World Health Organization, Geneva http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf.
10. [10] Sixty-seventh World Health Assembly. Resolution WHA67.6 on hepatitis. 2014, World Health Organization, Geneva http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf.
11. [11] WHO global health sector strategy on viral hepatitis. 2016, World Health Organization, Geneva http://www.who.int/hepatitis/strategy2016-2021/Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf?ua=1.
12. [12] Prevention and control of viral hepatitis infection: Framework for global action. 2012, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/130012/1/WHO_HSE_PED_HIP_GHP_2012.1_eng.pdf.
13. [13] Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. 2013, National Institute for Health and Care Excellence guidance.nice.org.uk/ph43.
14. [14] National hepatitis C testing policy. 2012, Australian Society for HIV Medicine http://testingportal.ashm.org.au/resources/HCV/2012_HCV_TESTING_POLICY_v1.1_Final.pdf.
15. [15] Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. 2012, Centers for Disease Control and Prevention, Atlanta http://www.cdc.gov/mmwr/pdf/rr/rr6104.pdf.
16. [16] HCV guidance. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 2015, Aaasld Idsa HCV Guidance Panel http://www.hcvguidelines.org/full-report-view.
17. [17] European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
18. [18] Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. 2016, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1.
19. [19] Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1.
20. [20] Consolidated guidelines on HIV testing services. 2015, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926_eng.pdf?ua=1&ua=1.
21. [21] Handbook for guidelines development. 2014, World Health Organization, Geneva http://www.who.int/kms/handbook_2nd_ed.pdf.
22. [22] Guyatt, G.H., Oxman, A.D., Kunz, R., Atkins, D., Brozek, J., Vist, G., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64 (2011), 395–400.
23. [23] Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
24. [24] Guyatt, G., Oxman, A.D., Akl, E.A., Kunz, R., Vist, G., Brozek, J., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64 (2011), 383–394.
25. [25] Andrews, J., Guyatt, G., Oxman, A.D., Alderson, P., Dahm, P., Falck-Ytter, Y., et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66 (2013), 719–725.
26. [26] Schunemann, H.J., Oxman, A.D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G.E., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008), 1106–1110.
27. [27] Whiting, P.F., Rutjes, A.W., Westwood, M.E., Mallett, S., Deeks, J.J., Reitsma, J.B., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155 (2011), 529–536.
28. [28] Easterbrook, P., Johnson, C., Figueroa, C., Baggaley, R., HIV and hepatitis testing: Global progress, challenges and future directions. AIDS Rev 18 (2016), 3–14.
29. [29] Global update on the health sector response to HIV. 2014, World Health Organization, Geneva http://www.who.int/hiv/pub/progressreports/update2014/en/.
30. [30] Kennedy, C.E., Fonner, V.A., Sweat, M.D., Okero, F.A., Baggaley, R., O'Reilly, K.R., Provider-initiated HIV testing and counseling in low- and middle-income countries: a systematic review. AIDS Behav 17 (2013), 1571–1590.
31. [31] Mutale, W., Michelo, C., Jürgensen, M., Fylkesnes, K., Home-based voluntary HIV counselling and testing found highly acceptable and to reduce inequalities. BMC Public Health, 10, 2010, 347.
32. [32] Suthar, A.B., Ford, N., Bachanas, P.J., Wong, V.J., Rajan, J.S., Saltzman, A.K., et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med., 10, 2013, e1001496.
33. [33] Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015, World Health Organization, Geneva http://www.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf.
34. [34] Policy Brief. WHO Guidelines on hepatitis B and C testing. 2016, World Health Organization, Geneva.
35. [35] Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
36. [36] Hagan, H., Jordan, A.E., Neurer, J., Cleland, C.M., Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 29 (2015), 2335–2345.
37. [37] Alonso, M., Gutzman, A., Mazin, R., Pinzon, C.E., Reveiz, L., Ghidinelli, M., Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health 60 (2015), 789–798.
38. [38] Chen, Y., Shen, Z., Morano, J.P., Khoshnood, K., Wu, Z., Lan, G., et al. Bridging the epidemic: a comprehensive analysis of prevalence and correlates of HIV, hepatitis C, and syphilis, and infection among female sex workers in Guangxi Province, China. PLoS One, 10, 2015, e0115311.
39. [39] Rein, D.B., Smith, B.D., Wittenborn, J.S., Lesesne, S.B., Wagner, L.D., Roblin, D.W., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 156 (2012), 263–270.
40. [40] Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
41. [41] Blood donor selection: guidelines on assessing donor suitability for blood donation. 2012, World Health Organization, Geneva.
42. [42] Geue, C., Wu, O., Xin, Y., Heggie, R., Hutchinson, S., Martin, N.K., et al. Cost-effectiveness of HBV and HCV screening strategies - a systematic review of existing modelling techniques. PLoS One, 10, 2015, e0145022.
43. [43] Castelnuovo, E., Thompson-Coon, J., Pitt, M., Cramp, M., Siebert, U., Price, A., et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 10 (2006), iii–iv [ix–xii, 1–93].
44. [44] Loubiere, S., Rotily, M., Moatti, J.P., Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care 19 (2003), 632–645.
45. [45] Loubiere, S., Rotily, M., Moatti, J.P., Medico-economic assessment of the therapeutic management of patients with hepatitis C. Gastroenterol Clin Biol 24 (2000), 1047–1051.
46. [46] Nakamura, J., Terajima, K., Aoyagi, Y., Akazawa, K., Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 215 (2008), 33–42.
47. [47] Singer, M.E., Younossi, Z.M., Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 111 (2001), 614–621.
48. [48] Stein, K., Dalziel, K., Walker, A., Jenkins, B., Round, A., Royle, P., Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. J Hepatol 39 (2003), 814–825.
49. [49] Coffin, P.O., Scott, J.D., Golden, M.R., Sullivan, S.D., Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 54 (2012), 1259–1271.
50. [50] McGarry, L.J., Pawar, V.S., Panchmatia, H.R., Rubin, J.L., Davis, G.L., Younossi, Z.M., et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 55 (2012), 1344–1355.
51. [51] Eckman, M.H., Talal, A.H., Gordon, S.C., Schiff, E., Sherman, K.E., Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 56 (2013), 1382–1393.
52. [52] Liu, S., Cipriano, L.E., Holodniy, M., Goldhaber-Fiebert, J.D., Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One, 8, 2013, e58975.
53. [53] Lapane, K.L., Jakiche, A.F., Sugano, D., Weng, C.S., Carey, W.D., Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 93 (1998), 591–596.
54. [54] Wong, W.W., Tu, H.A., Feld, J.J., Wong, T., Krahn, M., Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 187 (2015), E110–E121.
55. [55] Ruggeri, M., Coretti, S., Gasbarrini, A., Cicchetti, A., Economic assessment of an anti-HCV screening program in Italy. Value Health 16 (2013), 965–972.
56. [56] Honeycutt, A.A., Harris, J.L., Khavjou, O., Buffington, J., Jones, T.S., Rein, D.B., The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep 122 (2007), 55–62.
57. [57] Josset, V., Torre, J.P., Tavolacci, M.P., Van Rossem-Magnani, V., Anselme, K., Merle, V., et al. Efficiency of hepatitis C virus screening strategies in general practice. Gastroenterol Clin Biol 28 (2004), 351–357.
58. [58] Leal, P., Stein, K., Rosenberg, W., What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?. J Med Screen 6 (1999), 124–131.
59. [59] Stein, K., Dalziel, K., Walker, A., Jenkins, B., Round, A., Royle, P., Screening for Hepatitis C in injecting drug users: a cost utility analysis. J Public Health (Oxf) 26 (2004), 61–71.
60. [60] Sutton, A.J., Edmunds, W.J., Gill, O.N., Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health, 6, 2006, 170.
61. [61] Sutton, A.J., Edmunds, W.J., Sweeting, M.J., Gill, O.N., The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat 15 (2008), 797–808.
62. [62] Thompson Coon, J., Castelnuovo, E., Pitt, M., Cramp, M., Siebert, U., Stein, K., Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 23 (2006), 393–406.
63. [63] Tramarin, A., Gennaro, N., Compostella, F.A., Gallo, C., Wendelaar Bonga, L.J., Postma, M.J., HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des 14 (2008), 1655–1660.
64. [64] Schackman, B.R., Leff, J.A., Barter, D.M., DiLorenzo, M.A., Feaster, D.J., Metsch, L.R., et al. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 110 (2015), 129–143.
65. [65] Cipriano, L.E., Zaric, G.S., Holodniy, M., Bendavid, E., Owens, D.K., Brandeau, M.L., Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One, 7, 2012, e45176.
66. [66] Linas, B.P., Wong, A.Y., Schackman, B.R., Kim, A.Y., Freedberg, K.A., Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 55 (2012), 279–290.
67. [67] Plunkett, B.A., Grobman, W.A., Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 192 (2005), 1153–1161.
68. [68] Urbanus, A.T., van Keep, M., Matser, A.A., Rozenbaum, M.H., Weegink, C.J., van den Hoek, A., et al. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?. PLoS One, 8, 2013, e70319.
69. [69] Deuffic-Burban, S., Abiteboul, D., Lot, F., Branger, M., Bouvet, E., Yazdanpanah, Y., Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Gut 58 (2009), 105–110.
70. [70] Miners, A.H., Martin, N.K., Ghosh, A., Hickman, M., Vickerman, P., Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat 21 (2014), 616–623.
71. [71] Martin, N.K., Hickman, M., Miners, A., Hutchinson, S.J., Taylor, A., Vickerman, P., Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 3, 2013.
72. [72] Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 54 (2011), 1137–1144.
73. [73] Grebely, J., Matthews, G.V., Lloyd, A.R., Dore, G.J., Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis 57 (2013), 1014–1020.
74. [74] Martin, N.K., Hickman, M., Hutchinson, S.J., Goldberg, D.J., Vickerman, P., Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57 (2013), S39–S45.
75. [75] WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2012, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/77969/1/9789241504379_eng.pdf?ua=1.
76. [76] Guidance on prevention of viral hepatitis B and C among people who inject drugs. 2012, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/75357/1/9789241504041_eng.pdf?ua=1.
77. [77] Brogueira, P., Costa, A., Miranda, A., Peres, S., Baptista, T., Aldir, I., et al. Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients. J Int AIDS Soc, 17, 2014, 19601.
78. [78] Asrani, S.K., Davis, G.L., Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep, 16, 2014, 381.
79. [79] Sylvestre, D.L., Loftis, J.M., Hauser, P., Genser, S., Cesari, H., Borek, N., et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 81 (2004), 719–734.
80. [80] Gao, F., Talbot, E.A., Loring, C.H., Power, J.J., Dionne-Odom, J., Alroy-Preis, S., et al. Performance of the OraQuick HCV rapid antibody test for screening exposed patients in a hepatitis C outbreak investigation. J Clin Microbiol 52 (2014), 2650–2652.
81. [81] Hess, K.L., Fisher, D.G., Reynolds, G.L., Sensitivity and specificity of point-of-care rapid combination syphilis-HIV-HCV tests. PLoS One, 9, 2014, e112190.
82. [82] Hui, A.Y., Chan, F.K., Chan, P.K., Tam, J.S., Sung, J.J., Evaluation of anew rapid whole-blood serological test for hepatitis c virus. Acta Virol 46 (2002), 47–48.
83. [83] Kaur, H., Dhanao, J., Oberoi, A., Evaluation of rapid kits for detection of HIV, HBsAg and HCV infections. Indian J Med Sci 54 (2000), 432–434.
84. [84] Lee, S.R., Kardos, K.W., Schiff, E., Berne, C.A., Mounzer, K., Banks, A.T., et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 172 (2011), 27–31.
85. [85] Al-Tahish, G., El-Barrawy, M.A., Hashish, M.H., Heddaya, Z., Effectiveness of three types of rapid tests for the detection of hepatitis C virus antibodies among blood donors in Alexandria, Egypt. J Virol Methods 189 (2013), 370–374.
86. [86] Buti, M., Cotrina, M., Chan, H., Jardi, R., Rodriguez, F., Costa, X., et al. Rapid method for the detection of anti-HCV antibodies in patients with chronic hepatitis C. Rev Esp Enferm Dig 92 (2000), 140–146.
87. [87] Cha, Y.J., Park, Q., Kang, E.S., Yoo, B.C., Park, K.U., Kim, J.W., et al. Performance evaluation of the OraQuick hepatitis C virus rapid antibody test. Ann Lab Med 33 (2013), 184–189.
88. [88] da Rosa, L., Dantas-Correa, E.B., Narciso-Schiavon, J.L., Schiavon, Lde L., Diagnostic Performance of Two Point-of-Care Tests for Anti-HCV Detection. Hepat Mon, 13, 2013, e12274.
89. [89] Ibrahim, S., Al Attas, S.A., Mansour, G.A., Ouda, S., Fallatah, H., Accuracy of rapid oral HCV diagnostic test among a Saudi sample. Clin Oral Invest 19 (2015), 475–480.
90. [90] Jewett, A., Smith, B.D., Garfein, R.S., Cuevas-Mota, J., Teshale, E.H., Weinbaum, C.M., Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego. CA J Clin Virol 54 (2012), 213–217.
91. [91] Kosack, C.S., Nick, S., Shanks, L., Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies. J Virol Methods 204 (2014), 6–10.
92. [92] Kim, M.H., Kang, S.Y., Lee, W.I., Evaluation of a new rapid test kit to detect hepatitis C virus infection. J Virol Methods 193 (2013), 379–382.
93. [93] Montebugnoli, L., Borea, G., Miniero, R., Sprovieri, G., A rapid test for the visual detection of anti-hepatitis C virus antibodies in whole blood. Clin Chim Acta 288 (1999), 91–96.
94. [94] Poovorawan, Y., Theamboonlers, A., Chumdermpadetsuk, S., Thong, C.P., Comparative results in detection of HCV antibodies by using a rapid HCV test, ELISA and immunoblot. Southeast Asian J Trop Med Public Health 25 (1994), 647–649.
95. [95] Scalioni Lde, P., Cruz, H.M., de Paula, V.S., Miguel, J.C., Marques, V.A., Villela-Nogueira, C.A., et al. Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations. J Clin Virol 60 (2014), 200–205.
96. [96] Smith, B.D., Drobeniuc, J., Jewett, A., Branson, B.M., Garfein, R.S., Teshale, E., et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 204 (2011), 825–831.
97. [97] Yaari, A., Tovbin, D., Zlotnick, M., Mostoslavsky, M., Shemer-Avni, Y., Hanuka, N., et al. Detection of HCV salivary antibodies by a simple and rapid test. J Virol Methods 133 (2006), 1–5.
98. [98] Daniel, H.D., Abraham, P., Raghuraman, S., Vivekanandan, P., Subramaniam, T., Sridharan, G., Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies. J Clin Microbiol 43 (2005), 1977–1978.
99. [99] Drobnik, A., Judd, C., Banach, D., Egger, J., Konty, K., Rude, E., Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health 101 (2011), 2151–2155.
100. [100] Lee, S.R., Yearwood, G.D., Guillon, G.B., Kurtz, L.A., Fischl, M., Friel, T., et al. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol 48 (2010), 15–17.
101. [101] Mvere, D., Constantine, N.T., Katsawde, E., Tobaiwa, O., Dambire, S., Corcoran, P., Rapid and simple hepatitis assays: encouraging results from a blood donor population in Zimbabwe. Bull World Health Organ 74 (1996), 19–24.
102. [102] Njouom, R., Tejiokem, M.C., Zanga, M.C., Pouillot, R., Ayouba, A., Pasquier, C., et al. A cost-effective algorithm for the diagnosis of Hepatitis C virus infection and prediction of HCV viremia in Cameroon. J Virol Methods 133 (2006), 223–226.
103. [103] O'Connell, R.J., Gates, R.G., Bautista, C.T., Imbach, M., Eggleston, J.C., Beardsley, S.G., et al. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings. Transfusion 53 (2013), 505–517.
104. [104] Yuen, M.F., Hui, C.K., Yuen, J.C., Young, J.L., Lai, C.L., The accuracy of SM-HCV rapid test for the detection of antibody to hepatitis C virus. Am J Gastroenterol 96 (2001), 838–841.
105. [105] Lee S, Kardos K, Yearwood G, Kurtz L, Roehler M, Feiss G. Results of a multi-center evaluation of a new rapid test for detection of hcv infection using whole blood, serum, plasma and oral fluid. International Liver Congress™ 2010 – the 45th annual meeting of the European Association for the Study of the Liver (EASL); Vienna, Austria: J Hepatol; 2010, p. S271.
106. [106] Hepatitis C: diagnostics technology landscape. 1st ed., 2015, World Health Organization, UNITAID Geneva http://unitaid-hepC-dx-tech-landscape-report_2015.html.
107. [107] Tanaka, E., Kiyosawa, K., Matsumoto, A., Kashiwakuma, T., Hasegawa, A., Mori, H., et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 23 (1996), 1330–1333.
108. [108] Tillmann, H.L., Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol 20 (2014), 6701–6706.
109. [109] Lee, S.C., Antony, A., Lee, N., Leibow, J., Yang, J.Q., Soviero, S., et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 38 (2000), 4171–4179.
110. [110] Yu, M.L., Chuang, W.L., Dai, C.Y., Chen, S.C., Lin, Z.Y., Hsieh, M.Y., et al. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test. J Clin Microbiol 38 (2000), 2933–2939.
111. [111] Sabato, M.F., Shiffman, M.L., Langley, M.R., Wilkinson, D.S., Ferreira-Gonzalez, A., Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol 45 (2007), 2529–2536.
112. [112] Vermehren, J., Kau, A., Gartner, B.C., Gobel, R., Zeuzem, S., Sarrazin, C., Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46 (2008), 3880–3891.
113. [113] Buket, C.A., Ayse, A., Selcuk, K., Suleyman, O., Emel, S.C., Comparison of HCV core antigen and anti-HCV with HCV RNA results. Afr Health Sci 14 (2014), 816–820.
114. [114] Chevaliez, S., Soulier, A., Poiteau, L., Bouvier-Alias, M., Pawlotsky, J.M., Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol 61 (2014), 145–148.
115. [115] Descamps, V., Op de Beeck, A., Plassart, C., Brochot, E., Francois, C., Helle, F., et al. Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol 50 (2012), 465–468.
116. [116] Durante-Mangoni, E., Vallefuoco, L., Sorrentino, R., Iossa, D., Perna, E., Molaro, R., et al. Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. J Med Virol 85 (2013), 1913–1918.
117. [117] Thong, V.D., Akkarathamrongsin, S., Avihingsanon, A., Theamboonlers, A., Poovorawan, Y., Tangkijvanich, P., The correlation between hepatitis C core antigen and hepatitis C virus RNA levels with respect to human immunodeficiency virus status, hepatitis C virus genotype and interferon-lambda-4 polymorphism. Intervirology 58 (2015), 73–79.
118. [118] Ergunay, K., Sener, B., Alp, A., Karakaya, J., Hascelik, G., Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis 70 (2011), 486–491.
119. [119] Florea, D., Neaga, E., Nicolae, I., Maxim, D., Popa, M., Otelea, D., Clinical usefulness of HCV core antigen assay for the management of patients with chronic hepatitis C. J Gastrointestin Liver Dis 23 (2014), 393–396.
120. [120] Garbuglia, A.R., Monachetti, A., Galli, C., Sabatini, R., Ferreri, M.L., Capobianchi, M.R., et al. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. BMC Infect Dis, 14, 2014, 222.
121. [121] Gu, J., Yu, T., Liang, Z., Performances of HCV Ag or HCV RNA kits for screening of HCV-infected samples. Chin J Biol 27 (2014), 1181–1184.
122. [122] Hadziyannis, E., Minopetrou, M., Georgiou, A., Spanou, F., Koskinas, J., Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol 26 (2013), 146–149.
123. [123] Heidrich, B., Pischke, S., Helfritz, F.A., Mederacke, I., Kirschner, J., Schneider, J., et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. J Viral Hepat 21 (2014), 769–779.
124. [124] Kadkhoda, K., Smart, G., HCV antigen testing for the diagnosis of hepatitis C infection: a cost-efficient algorithm. Clin Lab 60 (2014), 677–680.
125. [125] Kesli, R., Polat, H., Terzi, Y., Kurtoglu, M.G., Uyar, Y., Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol 49 (2011), 4089–4093.
126. [126] Köroğlu, M., Ak, S., Ak, M., Yakupoğulları, Y., Özer, A., Evaluation of diagnostic performance of new antigen-based enzyme immune assay for diagnosis of Hepatitis C virus (HCV) infections. Afr J Microbiol Res 6 (2012), 809–812.
127. [127] Kuo, Y.H., Chang, K.C., Wang, J.H., Tsai, P.S., Hung, S.F., Hung, C.H., et al. Is hepatitis C virus core antigen an adequate marker for community screening?. J Clin Microbiol 50 (2012), 1989–1993.
128. [128] Li Cavoli, G., Zagarrigo, C., Schillaci, O., Servillo, F., Tralongo, A., Coglitore, M., et al. Hepatitis C virus core antigen test in monitoring of dialysis patients. Hepat Res Treat, 2012, 2012, 832021.
129. [129] Mederacke I, Ciesek S, Raupach R, Wursthorn K, Deterding K, Steinmann E, et al. Kinetics of HCV core antigen during antiviral treatment of acute and chronic hepatitis C as determined by a novel chemiluminescent microparticle immunoassay. In: Hepatology Jo, editor. The international Liver CongressTM 2009 44th annual meeting of the European Associateion for the Study of the Liver (EASL); Copenhagen, Denmark; 2009, p. S129.
130. [130] Mederacke, I., Potthoff, A., Meyer-Olson, D., Meier, M., Raupach, R., Manns, M.P., et al. HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol 53 (2012), 110–115.
131. [131] Medici, M.C., Furlini, G., Rodella, A., Fuertes, A., Monachetti, A., Calderaro, A., et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 51 (2011), 264–269.
132. [132] Miedouge, M., Saune, K., Kamar, N., Rieu, M., Rostaing, L., Izopet, J., Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 48 (2010), 18–21.
133. [133] Murayama, A., Sugiyama, N., Watashi, K., Masaki, T., Suzuki, R., Aizaki, H., et al. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol 50 (2012), 1943–1949.
134. [134] Ottiger, C., Gygli, N., Huber, A.R., Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol 58 (2013), 535–540.
135. [135] Park, Y., Lee, J.H., Kim, B.S., Kim do, Y., Han, K.H., Kim, H.S., New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 48 (2010), 2253–2256.
136. [136] Reyes-Mendez, M.A., Juarez-Figueroa, L., Iracheta-Hernandez, P., Medina-Islas, Y., Ruiz-Gonzalez, V., Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test. Ann Hepatol 13 (2014), 337–342.
137. [137] Rouet, F., Deleplancque, L., Mboumba, B.B., Sica, J., Mouinga-Ondeme, A., Liegeois, F., et al. Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV-positive adults from Gabon (Central Africa). PLoS One, 10, 2015, e0116975.
138. [138] Russi, S., Sansonno, D., Mariggio, M.A., Vinella, A., Pavone, F., Lauletta, G., et al. Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia. Arthritis Res Ther, 16, 2014, R73.
139. [139] Tedder, R.S., Tuke, P., Wallis, N., Wright, M., Nicholson, L., Grant, P.R., Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J Viral Hepat 20 (2013), 65–71.
140. [140] van Helden, J., Weiskirchen, R., Hepatitis C diagnostics: clinical evaluation of the HCV-core antigen determination. Z Gastroenterol 52 (2014), 1164–1170.
141. [141] Vanhommerig, J.W., van de Laar, T.J., Koot, M., van Rooijen, M.S., Schinkel, J., Speksnijder, A.G., et al. Evaluation of a hepatitis C virus (HCV) antigen assay for routine HCV screening among men who have sex with men infected with HIV. J Virol Methods 213 (2015), 147–150.
142. [142] Vermehren, J., Susser, S., Berger, A., Perner, D., Peiffer, K.H., Allwinn, R., et al. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 55 (2012), 17–22.
143. [143] Laperche, S., Le Marrec, N., Girault, A., Bouchardeau, F., Servant-Delmas, A., Maniez-Montreuil, M., et al. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 43 (2005), 3877–3883.
144. [144] Nastouli, E., Thomson, E.C., Karayiannis, P., Main, J., McClure, M., Muir, D., Diagnosing acute hepatitis C in HIV-infected patients: nucleic acid testing compared with antibody and antigen-antibody detecting methods. J Clin Virol 44 (2009), 78–80.
145. [145] Schnuriger, A., Dominguez, S., Valantin, M.A., Tubiana, R., Duvivier, C., Ghosn, J., et al. Early detection of hepatitis C virus infection using a new combined antigen-antibody detection assay: potential use in HIV co-infected individuals. Pathol Biol (Paris) 54 (2006), 578–586.
146. [146] Tuke, P.W., Grant, P.R., Waite, J., Kitchen, A.D., Eglin, R.P., Tedder, R.S., Hepatitis C virus window-phase infections: closing the window on hepatitis C virus. Transfusion 48 (2008), 594–600.
147. [147] Vermeersch, P., Van Ranst, M., Lagrou, K., Evaluation of the use of a combined HCV antigen/antibody assay in routine laboratory practice. Acta Clin Belg 65 (2010), 245–247.
148. [148] Saito, R., Yokota, H., Takahashi, E., Mashige, F., Yoneyama, A., Nakahara, K., et al. Performance of an automated system for quantitation of hepatitis C virus core antigen. J Virol Methods 112 (2003), 93–97.
149. [149] Lu, Y.C., Jiang, Z.Y., Kuang, Y.L., Chen, W.S., Tan, Y.Z., Li, D.R., Clinical value of the detection of hepatitis C virus core antigen. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23 (2007), 635–637.
150. [150] Ouyang, Y., Tan, D.M., Li, T.G., Zhou, H., Tan, C., Qualitative detection of hepatitis C virus core antigen in the serum in patients with chronic hepatitis C. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31 (2006), 894–896 905.
151. [151] Zhang, H.Q., Li, S.B., Wang, G.H., Chen, K., Song, X.G., Feng, X.Y., Detection of hepatitis C virus core antigen for early diagnosis of hepatitis C virus infection in plasma donor in China. World J Gastroenterol 13 (2007), 2738–2742.
152. [152] Zhu, H., Zhang, T., Fan, C., Xiao, X., Zhang, F., Clinical significance of testing hepatitis C virus core antigen. J Dalian Med Univ 32 (2010), 211–212.
153. [153] Alzahrani, A.J., Simultaneous detection of hepatitis C virus core antigen and antibodies in Saudi drug users using a novel assay. J Med Virol 80 (2008), 603–606.
154. [154] El-Emshaty, W.M., Raafat, D., Elghannam, D.M., Saudy, N., Eltoraby, E.E., Metwalli, A.E., Diagnostic performance of an immunoassay for simultaneous detection of HCV core antigen and antibodies among haemodialysis patients. Braz J Microbiol 42 (2011), 303–309.
155. [155] Yang, J.F., Lin, Y.Y., Hsieh, M.H., Tsai, C.H., Liu, S.F., Yu, M.L., et al. Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups. Kaohsiung J Med Sci 27 (2011), 258–263.
156. [156] Agha, S., Tanaka, Y., Saudy, N., Kurbanov, F., Abo-Zeid, M., El-Malky, M., et al. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol 73 (2004), 216–222.
157. [157] El-Sayed Zaki, M., El-Adrosy, H., Recent approach for diagnosis of early HCV infection. Egypt J Immunol 11 (2004), 123–129.
158. [158] Letowska, M., Brojer, E., Mikulska, M., Gronowska, A., Rosiek, A., Hepatitis C core antigen in Polish blood donors. Transfusion 44 (2004), 1067–1071.
159. [159] Nubling, C.M., Unger, G., Chudy, M., Raia, S., Lower, J., Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 42 (2002), 1037–1045.
160. [160] Ohta, H., Takemura, M., Furuta, N., Akiyama, M., Katagiri, Y., Ohashi, H., et al. Clinical significance and problems in HCV measurement–comparison of CLEIA method with PCR method. Rinsho Byori 52 (2004), 813–818.
161. [161] Okazaki, K., Nishiyama, Y., Saitou, T., Shibata, N., Yamamoto, C., Oosaga, J., et al. Fundamental evaluation of HCV core antigen method comparison with Cobas Amplicor HCV monitor v2.0 (high range method). Rinsho Byori 56 (2008), 95–100.
162. [162] Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med, 2016, 10.7326/M16-0065.
163. [163] EASL Clinical Practice Guidelines: management of hepatitis C virus infection. 2014, European Association for the Study of Liver http://www.ncbi.nlm.nih.gov/pubmed/24331294.
164. [164] Thomson, E.C., Fleming, V.M., Main, J., Klenerman, P., Weber, J., Eliahoo, J., et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 60 (2011), 837–845.
165. [165] Moscato, G.A., Giannelli, G., Grandi, B., Pieri, D., Marsi, O., Guarducci, I., et al. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology 54 (2011), 61–65.
166. [166] Ford, N., Swan, T., Beyer, P., Hirnschall, G., Easterbrook, P., Wiktor, S., Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol 61 (2014), S132–S138.
167. [167] Loggi, E., Cursaro, C., Scuteri, A., Grandini, E., Panno, A.M., Galli, S., et al. Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol 56 (2013), 207–211.
168. [168] Fujino, T., Nakamuta, M., Aoyagi, Y., Fukuizumi, K., Takemoto, R., Yoshimoto, T., et al. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy. J Dig Dis 10 (2009), 21–25.
169. [169] Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., Ishii, H., Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 43 (2005), 186–191.
170. [170] Feng, B., Yang, R.F., Xie, Q., Shang, J., Kong, F.Y., Zhang, H.Y., et al. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterol, 14, 2014, 47.
171. [171] Snijdewind, I.J., van Kampen, J.J., Fraaij, P.L., van der Ende, M.E., Osterhaus, A.D., Gruters, R.A., Current and future applications of dried blood spots in viral disease management. Antiviral Res 93 (2012), 309–321.
172. [172] Gruner, N., Stambouli, O., Ross, R.S., Dried blood spots–preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp, 2015.
173. [173] Ross, R.S., Stambouli, O., Gruner, N., Marcus, U., Cai, W., Zhang, W., et al. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots–performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J, 10, 2013, 72.
174. [174] Brandao, C.P., Marques, B.L., Marques, V.A., Villela-Nogueira, C.A., Do, O.K., de Paula, M.T., et al. Simultaneous detection of hepatitis C virus antigen and antibodies in dried blood spots. J Clin Virol 57 (2013), 98–102.
175. [175] Tuaillon, E., Mondain, A.M., Meroueh, F., Ottomani, L., Picot, M.C., Nagot, N., et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 51 (2010), 752–758.
176. [176] O'Brien, J., Kruzel, K., Wandell, M., Vinogradov, I., Sheagren, J., Frank, A., Detection of hepatitis C antibody with at-home collection kits using an innovative laboratory algorithm. Infect Dis Clin Pract 10 (2001), 474–480.
177. [177] Croom, H.A., Richards, K.M., Best, S.J., Francis, B.H., Johnson, E.I., Dax, E.M., et al. Commercial enzyme immunoassay adapted for the detection of antibodies to hepatitis C virus in dried blood spots. J Clin Virol 36 (2006), 68–71.
178. [178] Marques, B.L., Brandao, C.U., Silva, E.F., Marques, V.A., Villela-Nogueira, C.A., Do, O.K., et al. Dried blood spot samples: optimization of commercial EIAs for hepatitis C antibody detection and stability under different storage conditions. J Med Virol 84 (2012), 1600–1607.
179. [179] Waterboer, T., Dondog, B., Michael, K.M., Michel, A., Schmitt, M., Vaccarella, S., et al. Dried blood spot samples for seroepidemiology of infections with human papillomaviruses, Helicobacter pylori, Hepatitis C Virus, and JC Virus. Cancer Epidemiol Biomarkers Prev 21 (2012), 287–293.
180. [180] Nandagopal, P., Iqbal, H.S., Saravanan, S., Solomon, S.S., Mehta, S., Selvakumar, M., et al. Evaluation of dried blood spot as an alternative specimen for the diagnosis of anti-HCV in resource-limited settings. Indian J Med Microbiol 32 (2014), 208–210.
181. [181] Dokubo, E.K., Evans, J., Winkelman, V., Cyrus, S., Tobler, L.H., Asher, A., et al. Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol 59 (2014), 223–227.
182. [182] Tejada-Strop, A., Drobeniuc, J., Mixson-Hayden, T., Forbi, J.C., Le, N.T., Li, L., et al. Disparate detection outcomes for anti-HCV IgG and HCV RNA in dried blood spots. J Virol Methods 212 (2015), 66–70.
183. [183] Chevaliez S, Soulier A, Poiteau L, Pawlotsky JM. Dried blood spots (DBS), a promising tool for large-scale hepatitis c screening, diagnosis and treatment monitoring. International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver (EASL); London, United Kingdom: J Hepatol; 2014.
184. [184] Larrat, S., Bourdon, C., Baccard, M., Garnaud, C., Mathieu, S., Quesada, J.L., et al. Performance of an antigen-antibody combined assay for hepatitis C virus testing without venipuncture. J Clin Virol 55 (2012), 220–225.
185. [185] Parker, S.P., Cubitt, W.D., Ades, A.E., A method for the detection and confirmation of antibodies to hepatitis C virus in dried blood spots. J Virol Methods 68 (1997), 199–205.
186. [186] Kania, D., Bekale, A.M., Nagot, N., Mondain, A.M., Ottomani, L., Meda, N., et al. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa. Clin Microbiol Infect 19 (2013), E533–E541.
187. [187] Lee, C.E., Sri Ponnampalavanar, S., Syed Omar, S.F., Mahadeva, S., Ong, L.Y., Kamarulzaman, A., Evaluation of the dried blood spot (DBS) collection method as a tool for detection of HIV Ag/Ab, HBsAg, anti-HBs and anti-HCV in a Malaysian tertiary referral hospital. Ann Acad Med Singapore 40 (2011), 448–453.
188. [188] Lukacs, Z., Dietrich, A., Ganschow, R., Kohlschutter, A., Kruithof, R., Simultaneous determination of HIV antibodies, hepatitis C antibodies, and hepatitis B antigens in dried blood spots–a feasibility study using a multi-analyte immunoassay. Clin Chem Lab Med 43 (2005), 141–145.
189. [189] McCarron, B., Fox, R., Wilson, K., Cameron, S., McMenamin, J., McGregor, G., et al. Hepatitis C antibody detection in dried blood spots. J Viral Hepat 6 (1999), 453–456.
190. [190] Shepherd, S.J., Kean, J., Hutchinson, S.J., Cameron, S.O., Goldberg, D.J., Carman, W.F., et al. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. J Clin Virol 57 (2013), 29–35.
191. [191] Abe, K., Konomi, N., Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. J Clin Microbiol 36 (1998), 3070–3072.
192. [192] Bennett, S., Gunson, R.N., McAllister, G.E., Hutchinson, S.J., Goldberg, D.J., Cameron, S.O., et al. Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol 54 (2012), 106–109.
193. [193] De Crignis, E., Re, M.C., Cimatti, L., Zecchi, L., Gibellini, D., HIV-1 and HCV detection in dried blood spots by SYBR Green multiplex real-time RT-PCR. J Virol Methods 165 (2010), 51–56.
194. [194] Soulier, A., Poiteau, L., Rosa, I., Hezode, C., Roudot-Thoraval, F., Pawlotsky, J.M., et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis 213 (2016), 1087–1095.
195. [195] Santos, C., Reis, A., Dos Santos, C.V., Damas, C., Silva, M.H., Viana, M.V., et al. The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically. J Virol Methods 179 (2012), 17–20.
196. [196] Solmone, M., Girardi, E., Costa, F., Pucillo, L., Ippolito, G., Capobianchi, M.R., Simple and reliable method for detection and genotyping of hepatitis C virus RNA in dried blood spots stored at room temperature. J Clin Microbiol 40 (2002), 3512–3514.
197. [197] Greenman, J., Roberts, T., Cohn, J., Messac, L., Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepat 22 (2015), 353–361.
198. [198] Solmone M, Girardi E, Costa F, Ippolito G, Capobianchi MR. Simple and reliable method for HCV-RNA detection/genotyping in dried blood spots. EASL International Consensus Conference on Hepatitis B; Geneva, Switzerland: J Hepatol; 2002, p. 131.
199. [199] Craine, N., Whitaker, R., Perrett, S., Zou, L., Hickman, M., Lyons, M., A stepped wedge cluster randomized control trial of dried blood spot testing to improve the uptake of hepatitis C antibody testing within UK prisons. Eur J Public Health 25 (2015), 351–357.
200. [200] McLeod, A., Weir, A., Aitken, C., Gunson, R., Templeton, K., Molyneaux, P., et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. J Epidemiol Community Health 68 (2014), 1182–1188.
201. [201] Place des tests rapides d'orientation diagnostique (TROD) dans la stratégie de dépistage de l'hépatite C. 2014, Haute Autorité Sanitaire, Saint-Denis La Plaine Cedex http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-05/place_des_trod_dans_la_strategie_de_depistage_de_vhc-_rapport.pdf.
202. [202] Hickman, M., McDonald, T., Judd, A., Nichols, T., Hope, V., Skidmore, S., et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat 15 (2008), 250–254.
203. [203] Kalibala, S., Tun, W., Cherutich, P., Nganga, A., Oweya, E., Oluoch, P., Factors associated with acceptability of HIV self-testing among health care workers in Kenya. AIDS Behav 18 (2014), S405–S414.
204. [204] Corbett, E.L., Dauya, E., Matambo, R., Cheung, Y.B., Makamure, B., Bassett, M.T., et al. Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. PLoS Med, 3, 2006, e238.
205. [205] Kebede, B., Abate, T., Mekonnen, D., HIV self-testing practices among Health Care Workers: feasibility and options for accelerating HIV testing services in Ethiopia. Pan Afr Med J, 15, 2013, 50.
206. [206] MacPherson, P., Lalloo, D.G., Webb, E.L., Maheswaran, H., Choko, A.T., Makombe, S.D., et al. Effect of optional home initiation of HIV care following HIV self-testing on antiretroviral therapy initiation among adults in Malawi: a randomized clinical trial. JAMA 312 (2014), 372–379.
207. [207] Choko, A.T., MacPherson, P., Webb, E.L., Willey, B.A., Feasy, H., Sambakunsi, R., et al. Uptake, accuracy, safety, and linkage into care over two years of promoting annual self-testing for HIV in Blantyre, Malawi: a community-based prospective study. PLoS Med, 12, 2015, e1001873.